Marsha says,
*****************************************************


If anything, I  think a company would
jump at making such a drug if they thought it would  be a *blockbuster*
drug.

******************************************************

The problem is (looking at a galactogogue from a pharmaceutical POV), how
many women in the U.S. are going to actually NEED the medication?  If I  look at
the percentage of moms that I see in a year that actually need  Domperidone
or Reglan, or even Fenugreek or another herbal, it is relatively  small.  I
don't think any company is going to find that these drugs are  "blockbusters".
That's why it seems a tad ludicrous that the FDA is even  paying the slightest
bit of attention to this issue with Domperidone.  In  the scheme of things,
this is penny ante.

If even 10% of the women who initiate breastfeeding in a given year  actually
NEED Domperidone or another medication to increase supply (and I think  that
is enormously high), that is still going to be only about 250,000  women --
tops.  So I don't think when one is looking at releasing a  medication, that
number justifies all the hoops a company has to jump thru to  get the drug.

So again, why the FDA has jumped into this particular fray is definitely a
question that needs to be answered......

Jan Barger, RN, MA, IBCLC
Wheaton  IL
www.lactationeducationconsultants.com

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html